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Introduction {#sec1}
============

Centrioles are evolutionarily conserved organelles that are pivotal for the formation of cilia, flagella, and centrosomes, and are thus critical for fundamental cellular processes such as signaling, polarity, motility, and division (reviewed in [@bib2], [@bib8], [@bib24], [@bib16]). Owing to their central role in such diverse cellular processes, centriole aberrations contribute to a range of severe human diseases, including ciliopathies, primary microcephaly, and cancer (reviewed in [@bib36], [@bib17]). Microtubules are the major constituent of centrioles and are arranged in a radial nine-fold symmetrical array, typically of triplet microtubules, which forms a barrel-shaped centriolar wall (reviewed in [@bib2], [@bib8], [@bib24], [@bib16]). Centriolar microtubules are unique in exhibiting exceptionally slow growth rates of a few tens of nanometers per hour on average, and in being very stable after their formation ([@bib31], [@bib11]). Such properties likely contribute to setting centriole length, which is well conserved across evolution. The behavior of centriolar microtubules is in stark contrast to that of their cytoplasmic counterparts, which assemble up to four orders of magnitude faster and are highly dynamic ([@bib27]). The molecular mechanisms that impart the exceptional slow growth rate and stability of centriolar microtubules are not known.

Several centriolar proteins that can directly interact with tubulin and/or microtubules have been identified, including CEP120, CEP135, Centrobin, and CPAP ([@bib19], [@bib33], [@bib34], [@bib22]). CPAP (SAS-4 in worms and flies) is of particular interest, since it is the only component among the ones listed above that is present and essential for centriole formation from worm to man ([@bib30], [@bib42], [@bib45], [@bib28], [@bib32]). The importance of CPAP is further substantiated by the fact that homozygous mutations in the corresponding gene lead to autosomal recessive primary microcephaly, a devastating human disease with drastically reduced neuron numbers and, thus, brain size ([@bib7]). Interestingly, CPAP overexpression induces overly long centrioles in human cells ([@bib30], [@bib42], [@bib45]), thus interfering with cell division ([@bib30]). Together, these observations suggest that CPAP somehow regulates centriolar microtubule growth to produce proper centrioles. How this role is exerted at a mechanistic level remains elusive.

CPAP comprises a tubulin-binding domain (PN2-3), a positively charged microtubule-binding domain (MBD), a coiled-coil dimerization domain, and a C-terminal G box ([Figure 1](#fig1){ref-type="fig"}A). The PN2-3 domain is of prime interest as this region is highly conserved across evolution and found exclusively in CPAP/SAS-4 proteins. PN2-3 sequesters tubulin dimers and has been shown to destabilize microtubules both in vitro and in cells ([@bib22], [@bib12], [@bib23]). How this observation can be reconciled with the presence of overly long centrioles upon CPAP overexpression, which is suggestive of the protein-enhancing centriolar microtubule elongation, has remained puzzling. Here, to elucidate the fundamental mechanism of action of CPAP/SAS-4 proteins, we set out to decipher how CPAP affects microtubules using structural, biophysical, and cell biological approaches. We first report a high-resolution structure of αβ-tubulin in complex with the PN2-3 domain of CPAP. This structural information guided the design of experiments aimed at understanding the key role of CPAP in regulating centriolar microtubule behavior. Using reconstitution experiments, we demonstrate that CPAP autonomously recognizes and tracks growing microtubule plus ends. There, CPAP suppresses microtubule polymerization and increases microtubule stability by inhibiting catastrophes and promoting rescues. We further establish that the PN2-3 domain of CPAP is critical in the cellular context to restrict the extent of centriolar microtubule elongation by acting as a molecular "cap."

Results {#sec2}
=======

Crystal Structure of the SAC Domain of CPAP in a Complex with Tubulin {#sec2.1}
---------------------------------------------------------------------

To gain insight into the molecular mechanism of tubulin binding by CPAP/SAS-4 proteins, we sought to crystallize the PN2-3 domain of human CPAP in complex with tubulin (see [Table S1](#mmc1){ref-type="supplementary-material"} for all constructs generated in the course of this study). Extensive crystallization trials with complexes of tubulin and PN2-3 variants were not met with success. However, adding the β-tubulin-binding darpin (D1; [@bib38]) allowed us to solve the ternary complex formed between PN2-3, αβ-tubulin, and D1 (denoted the D1-tubulin-PN2-3 complex) to 2.2 Å resolution by X-ray crystallography ([Figures 1](#fig1){ref-type="fig"}A--1C and [Table S2](#mmc1){ref-type="supplementary-material"}). As reported previously for other structures, the D1 molecule was bound at the tip of β-tubulin in the D1-tubulin-PN2-3 complex structure, a location involved in longitudinal tubulin-tubulin contacts within microtubules ([@bib38]). In addition, we found electron densities for residues 373--385 of PN2-3, which correspond to the evolutionarily conserved SAC domain of CPAP (for "Similar in SAS-4 and CPAP"; [@bib32], [@bib22], [@bib29]) ([Figure 1](#fig1){ref-type="fig"}B). In the PN2-3-tubulin-D1 complex structure, we found that SAC residues are engaged with both α- and β-tubulin subunits without affecting the overall conformation of the dimer (root-mean-square deviation of tubulin in the tubulin-D1 \[PDB: [4DRX](pdb:4DRX){#intref0010}\] and PN2-3-tubulin-D1 complex structures: 0.49 Å over 760 Cα atoms). The SAC-binding site on tubulin is shaped by hydrophobic and polar residues of helices αH11′, βH3′, βH5, and βH12, and loops βH8-S7 and βH11′-H12 ([Figure 1](#fig1){ref-type="fig"}C).

The SAC-tubulin interaction is characterized by an extensive water and non-water-mediated hydrogen-bonding network, as well as by hydrophobic contacts established between both main-chain and side-chain atoms of SAC and tubulin residues. Prominent SAC side-chain contacts involve Phe375 (βAsp414, βMet416, βGlu417, βGlu420), Leu376 (βHis192, βQln193, βGlu196), Lys377 (βGlu420), Arg378 (βGlu420, βAsn426), and Phe385 (αH406, αTrp407, βPro263). Pull-down experiments had implicated Lys377 and Arg378 in tubulin binding ([@bib22]), and our findings reveal the structural basis for their importance in this interaction.

Atomic Model of the Interaction of Tubulin and PN2-3 {#sec2.2}
----------------------------------------------------

Previous studies suggested that PN2-3 inhibits exchange of the nucleotide on β-tubulin and that residues situated N-terminal to SAC also interact with tubulin ([@bib12], [@bib22], [@bib23]). The D1-PN2-3-tubulin structure revealed that the N terminus of SAC is located close to the D1-binding site at the tip of β-tubulin ([Figure 1](#fig1){ref-type="fig"}D). We therefore reasoned that the presence of D1 might hinder access of this region of CPAP to its binding site. Accordingly, isothermal titration calorimetry (ITC) experiments demonstrated that whereas PN2-3 bound tubulin with an equilibrium dissociation constant (K~D~) of 47 ± 6 nM, the affinity of PN2-3 for tubulin-D1 dropped one order of magnitude ([Figure 2](#fig2){ref-type="fig"}A). Likewise, eribulin and maytansine, two drugs that bind near the D1- and nucleotide-binding site, and which also inhibit longitudinal tubulin-tubulin contacts in microtubules ([@bib38], [@bib39], [@bib1]), significantly impaired the affinity of PN2-3 for tubulin ([Figure 2](#fig2){ref-type="fig"}A). We conclude that the N-terminal part of PN2-3 binds to a site on the tip of β-tubulin engaged in longitudinal tubulin-tubulin interactions ([@bib12]); we therefore named this putative domain "LID". To test whether the hydrolysis state of the exchangeable nucleotide bound to β-tubulin is important for tubulin-PN2-3 complex formation, as previously suggested for PN2-3 of *Drosophila* DmSAS-4 ([@bib18]), we performed additional ITC experiments. As shown in [Figure S1](#mmc1){ref-type="supplementary-material"}, we found similar K~D~ values for the interaction between human CPAP PN2-3 and guanosine diphosphate (GDP)-, guanosine triphosphate (GTP)-, or GMPCPP-tubulin (maximal difference of 1.3-fold). We conclude that the hydrolysis state of the nucleotide bound to β-tubulin has at most a minor effect on tubulin-PN2-3 complex formation.

To assess whether SAC and LID can bind tubulin independently, we generated two corresponding peptides, SACp and LIDp, and analyzed their tubulin-binding properties by ITC. K~D~ values in the low micromolar range were obtained for the interactions between tubulin and either SACp or LIDp ([Figure 2](#fig2){ref-type="fig"}B). To investigate the importance of selected SAC and LID residues for tubulin binding, we conducted further ITC experiments with mutant variants of the PN2-3 domain. Mutation of the tubulin-interacting SAC residues Lys377 and Arg378 to glutamic acid (KR/EE), or of Phe375 and Phe385 to alanine (FF/AA), reduced the affinity of PN2-3 for tubulin by two orders of magnitude ([Figure 2](#fig2){ref-type="fig"}C; compare with wild-type PN2-3 in [Figure 2](#fig2){ref-type="fig"}A). We also tested a PN2-3 mutant in which three residues in a conserved region of LID (Phe338, Glu339, Tyr341; [Figure 1](#fig1){ref-type="fig"}A) were simultaneously mutated to alanine (FEY/AAA), and also in this case obtained a K~D~ in the low micromolar range ([Figure 2](#fig2){ref-type="fig"}C).

These results suggest that both SAC and LID can bind independently to tubulin with low micromolar affinities, and that they cooperate to give rise to a ∼100-fold tighter interaction with tubulin when present together. To test whether SAC and LID could bind in the context of microtubules, we used an atomic model of a microtubule based on a cryoelectron microscopy reconstruction at 3.5-Å resolution ([@bib50]). Interestingly, this analysis showed that both SAC and LID binding interfaces are located on the outer surface, at the distal tip of the microtubule, which has exposed β-tubulin subunits ([Figure 2](#fig2){ref-type="fig"}D). This result indicates that CPAP could specifically target microtubule plus ends via its PN2-3 domain.

CPAP Tracks Growing Microtubule Plus Ends In Vitro {#sec2.3}
--------------------------------------------------

To test the idea that CPAP targets microtubule plus ends, we performed in vitro reconstitution experiments whereby dynamic microtubules were grown from GMPCPP-stabilized seeds and imaged using a total internal reflection fluorescence (TIRF) microscopy-based assay ([@bib4], [@bib35]). Since purified full-length CPAP was insoluble in our hands, we engineered a soluble chimeric protein in which the PN2-3-MBD moiety was fused to the leucine zipper domain of the yeast transcriptional activator GCN4 ([@bib37]) to mimic the dimerization imparted by the endogenous coiled-coil domain of CPAP ([@bib51]), which is required for CPAP function in centriole duplication ([@bib29]), as well as to GFP (the resulting protein has been dubbed CPAP~mini~; [Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A).

We found that CPAP~mini~ bound weakly to the microtubule lattice; importantly, in addition, we found that CPAP~mini~ localized to, and tracked, one end of dynamic microtubules specifically ([Figures 3](#fig3){ref-type="fig"}B--3E). We determined that CPAP~mini~ bound the plus end of microtubules, distinguished as such because it is negative for the minus-end targeting protein CAMSAP3 ([Figure 3](#fig3){ref-type="fig"}D) ([@bib26]). CPAP~mini~ co-localized at growing microtubule tips with the plus-end tracking protein EB3 ([Figure 3](#fig3){ref-type="fig"}F). However, in contrast to EB3, the plus-end accumulation of which critically depends on microtubule growth ([@bib4], [@bib35]), CPAP~mini~ was enriched at one end of GMPCPP-stabilized microtubules even when soluble tubulin was present at a concentration insufficient for microtubule elongation (5 instead of 15 μM tubulin; [Figure S2](#mmc1){ref-type="supplementary-material"}B). These data reveal that microtubule growth is not required for plus-end recognition by CPAP~mini~. In the absence of soluble tubulin, CPAP~mini~ localized along the entire length of GMPCPP-stabilized microtubules (data not shown), indicating that the interaction of CPAP~mini~ with soluble tubulin suppresses its binding to the microtubule lattice. Overall, we conclude that CPAP~mini~ is an autonomous microtubule plus-end tracking protein.

CPAP Promotes Slow and Processive Microtubule Growth In Vitro {#sec2.4}
-------------------------------------------------------------

We set out to determine the impact of CPAP~mini~ on microtubule dynamics. Strikingly, we found that CPAP~mini~ strongly reduced the rate of microtubule growth ([Figures 3](#fig3){ref-type="fig"}E and 3H). This effect could not be explained by tubulin sequestration, because the concentration of CPAP~mini~ in these experiments (75--100 nM) was much lower than that of tubulin (15 μM). Furthermore, CPAP~mini~ dramatically reduced the frequency of catastrophes and promoted rescues, together leading to highly processive microtubule polymerization ([Figures 3](#fig3){ref-type="fig"}E, 3I, and 3J). This effect was also observed in the presence of EB3, despite the fact that EB3 itself causes a ∼1.5-fold increase in microtubule growth rate and a ∼3-fold increase in catastrophe frequency ([Figures 3](#fig3){ref-type="fig"}F and 3K--3M). To test whether the artificial dimerization domain of GCN4 in CPAP~mini~ has an influence on microtubule dynamics, we purified a CPAP construct that contains the endogenous coiled coil (CPAP~long~; [Figures S2](#mmc1){ref-type="supplementary-material"}A and S2C). Although CPAP~long~ had a higher propensity for degradation and aggregation, it also bound to microtubule plus ends, very similarly to CPAP~mini~, and had a similar effect on microtubule dynamics: it reduced both the growth rate and the catastrophe frequency, and increased the rescue frequency ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2G). These data demonstrate that GCN4 links CPAP~mini~ polypeptide chains in a fashion similar to that of the endogenous coiled-coil domain.

Next, we tested the effect of mutations that disrupt either the tubulin-SAC (KR/EE, FF/AA) or the tubulin-LID interaction (ΔLID, FEY/AAA) on the ability of CPAP~mini~ to regulate microtubule plus-end dynamics ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). We found that all four mutants abrogated tip enrichment, as well as the effects on microtubule growth and catastrophes ([Figures 3](#fig3){ref-type="fig"}G--3L and [S2](#mmc1){ref-type="supplementary-material"}H). In contrast, all mutants, as well as the dimeric version of MBD alone (ΔPN2-3), were still able to bind to the microtubule lattice and induce rescues to an extent similar to that of wild-type CPAP~mini~ ([Figures 3](#fig3){ref-type="fig"}G--3M). This result suggests that the MBD has microtubule-stabilizing properties. To further assess the mechanism underlying the activity of CPAP~mini~, we investigated how its concentration affects microtubule dynamics. As mentioned above, at 75 nM of CPAP~mini~, though not at lower concentrations, both the microtubule growth rate and the catastrophe frequency were strongly reduced ([Figures 3](#fig3){ref-type="fig"}H--3L, [4](#fig4){ref-type="fig"}A, and 4B). A 4-fold increase in concentration of CPAP~mini~ had little additional effect on the microtubule growth rate and catastrophe frequency, indicating that the effect of CPAP~mini~ on microtubule elongation in vitro saturates at ∼75 nM ([Figures 4](#fig4){ref-type="fig"}A and 4B).

We next set out to determine the number of CPAP~mini~ molecules at microtubule plus ends. Single-molecule fluorescence intensity analysis of CPAP~mini~ in comparison with GFP confirmed that CPAP~mini~ is a dimer ([Figure 4](#fig4){ref-type="fig"}C). To determine the number of CPAP~mini~ molecules at one microtubule tip, we immobilized single CPAP~mini~ molecules on the surface of one flow chamber and performed the in vitro reconstitution assay in the adjacent chamber on the same coverslip. Images of unbleached CPAP~mini~ single molecules were acquired first, after which time-lapse imaging of the in vitro assay with CPAP~mini~ was performed using the same illumination and imaging conditions. We found that approximately two dimers of CPAP~mini~ were present at microtubule tips in the presence of 100 or 300 nM protein, respectively ([Figures 4](#fig4){ref-type="fig"}D and 4E). Our tubulin-PN2-3 structural model suggests that CPAP~mini~, which contains two PN2-3 moieties, interacts with microtubule plus ends by binding to terminal β-tubulin subunits ([Figure 2](#fig2){ref-type="fig"}D). Our reconstitution data thus indicate that CPAP~mini~ can reach its full activity with respect to microtubule growth inhibition and catastrophe suppression by binding to approximately four protofilaments.

To acquire mechanistic insights into CPAP~mini~ association with the microtubule tip and lattice, we mixed 5 nM CPAP~mini~-GFP ([Figure 4](#fig4){ref-type="fig"}F) with 100 nM CPAP~mini~-mCherry. This approach allowed us to observe the behavior of single CPAP~mini~-GFP molecules in conditions whereby the protein inhibits microtubule growth. Rapid imaging of such samples showed that in most cases CPAP~mini~ directly associated with the microtubule plus end, where it remained stationary and then detached. Occasionally, we observed CPAP~mini~ molecules diffusing toward or away from the microtubule tip ([Figure 4](#fig4){ref-type="fig"}F). The analysis of binding events of CPAP~mini~ at growing microtubule plus ends yielded an exponential dwell-time distribution with a mean value of ∼1.7 s (corrected for photobleaching \[[@bib21]\]) ([Figures 4](#fig4){ref-type="fig"}G, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). The dwell time for CPAP~mini~ was longer than those observed previously for EB1, EB3, and CLIP-170 in similar conditions (values ranged between ∼0.05 and 0.3 s \[[@bib5], [@bib35]\]). We also observed binding and unbinding of CPAP~mini~ to the microtubule lattice, with an average dwell time of ∼0.5 s ([Figures 4](#fig4){ref-type="fig"}G, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). On the lattice, both stationary and mobile CPAP~mini~ molecules were detected. We noted that a single CPAP~mini~ molecule could switch between the two types of behavior ([Figure 4](#fig4){ref-type="fig"}F). Automated single-particle tracking combined with mean squared displacement (MSD) analysis indicated that the mobile CPAP~mini~ molecule population undergoes one-dimensional diffusion, as the increase of the MSD value over time was linear ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E) ([@bib40]). The diffusion coefficient of CPAP~mini~ bound to microtubule lattices was 0.03 ± 0.0004 μm^2^ s^−1^ ([Table S3](#mmc1){ref-type="supplementary-material"}). This value is three times lower than that for EB3 and similar to the one for the kinesin-13 MCAK, obtained under similar conditions ([@bib35]).

Taken together, these results demonstrate that CPAP~mini~ localizes to microtubule plus ends mostly through direct binding and remains largely immobile at the microtubule tip until detachment. This behavior, as well as the longer dwell times at the microtubule plus end compared with the lattice, can be explained by the presence of the LID domain, which can attach CPAP~mini~ to the tip of a protofilament. Our data further show that CPAP~mini~ can either diffuse along the lattice or bind to it in a stationary manner. We think that these two types of CPAP~mini~ behavior might be due to the presence of the MBD and SAC domains, which can independently interact with microtubule lattices. Finally, our results demonstrate that CPAP~mini~ suppresses microtubule growth and stabilizes microtubules by inhibiting catastrophes and promoting rescues. In combination with the structural and biophysical data, our reconstitution data suggest that CPAP~mini~ ensures slow processive microtubule growth by capping and stabilizing the plus ends of protofilaments ([Figure 4](#fig4){ref-type="fig"}H).

Both the SAC and MBD Domains of CPAP Are Essential for Centriole Assembly {#sec2.5}
-------------------------------------------------------------------------

Our in vitro observations raised the possibility that CPAP could contribute to centriole formation in two ways: the MBD could promote centriolar microtubule assembly by stabilizing microtubules, while LID, together with SAC, might limit centriolar microtubule elongation by slowing growth of their plus ends. To test these predictions in the cellular context, we generated cell lines conditionally expressing YFP-tagged CPAP transgenes resistant to RNAi targeting endogenous CPAP ([@bib29]). We analyzed mitotic cells using the centriolar marker Centrin 2 as a readout of successful centriole assembly. Whereas \>90% of control cells contained ≥4 centrioles, this was the case for fewer than 10% of cells depleted of endogenous CPAP ([Figures 5](#fig5){ref-type="fig"}A, 5B, 5I, and [S4](#mmc1){ref-type="supplementary-material"}A) ([@bib30], [@bib42], [@bib45]). YFP-CPAP rescued this phenotype to a large extent, with \>80% of cells having successfully duplicated their centrioles ([Figures 5](#fig5){ref-type="fig"}C, 5I, and [S4](#mmc1){ref-type="supplementary-material"}A) ([@bib30], [@bib42], [@bib45]). Strikingly, we found that the removal of MBD (ΔMBD) completely abolished centriole assembly, to levels that are even lower than depletion of CPAP alone, likely due to dominant-negative effects following heterodimerization of YFP-CPAP-ΔMBD with any residual endogenous CPAP ([Figures 5](#fig5){ref-type="fig"}D, 5I, and [S4](#mmc1){ref-type="supplementary-material"}A). We conclude that the microtubule-stabilizing effect of MBD observed in vitro is essential for centriole biogenesis.

We found also that CPAP constructs lacking the LID domain or with key residues mutated, YFP-CPAP-ΔLID and FEY/AAA, respectively, were able to sustain centriole assembly in ∼65% of cells ([Figures 5](#fig5){ref-type="fig"}G--5I), indicating that LID contributes to, but is not essential for, this process. In contrast, CPAP function was severely compromised upon mutation of SAC (KR/EE or FF/AA; [Figures 5](#fig5){ref-type="fig"}E, 5F, and 5I), in line with previous findings ([@bib22], [@bib29], [@bib45]). Impaired function of all CPAP mutants likely reflects an impact on protein activity, because localization and turnover at the centrosome were unaffected ([Figures 5](#fig5){ref-type="fig"}C--5H and [S4](#mmc1){ref-type="supplementary-material"}B). Overall, these results establish that MBD and SAC are critical for centriole assembly, whereas LID appears to play an accessory role in this process.

CPAP Regulates the Length of Centriolar Microtubules in Cells {#sec2.6}
-------------------------------------------------------------

We further investigated the function of SAC and LID by analyzing cells depleted of endogenous CPAP and overexpressing YFP-CPAP variants, which provided us with an assay system to address the contribution of distinct domains of CPAP to centriole biogenesis. In these conditions, wild-type YFP-CPAP leads to the formation of overly long centrioles that contain not only CPAP but also other centriolar markers such as Centrin 2 along their entire length ([Figures 6](#fig6){ref-type="fig"}A and 6D), as reported for cells overexpressing wild-type CPAP in addition to having the endogenous protein ([@bib30], [@bib42], [@bib45]). In contrast, we found no overly long centrioles upon YFP-CPAP-ΔMBD overexpression ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), as anticipated from the fact that MBD is essential for centriole assembly. Mutation of SAC (KR/EE or FF/AA) led to a reduction in the proportion of cells with overly long centrioles while deletion of LID had no such effect, again reflecting the respective impact of these variants on the ability of CPAP to sustain regular centriole assembly ([Figures 6](#fig6){ref-type="fig"}A, 6D, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D).

Intriguingly, close examination of cells depleted of endogenous CPAP and overexpressing either YFP-CPAP-FF/AA or YFP-CPAP-ΔLID revealed the presence of extended YFP-positive fibers that stemmed from centrosomes, but which did not contain centriolar markers along their length ([Figures 6](#fig6){ref-type="fig"}A and 6C). To determine whether such centrosomal fibers originated from centrioles or from the pericentriolar matrix, we conducted immunofluorescence experiments with a marker surrounding the proximal end of parental centrioles (CEP63) and one marking the distal end of all centrioles (Centrin 2). This analysis revealed that ∼80% of centrosomal fibers appeared to be continuations of the distal end of regular centrioles or of overly long centrioles, and were thus termed centriole fibers ([Figures 6](#fig6){ref-type="fig"}E and 6F). These fibers, lacking Centrin, were often considerably longer than overly long centrioles bearing Centrin ([Figure 6](#fig6){ref-type="fig"}H) and were positive for α-tubulin ([Figures 6](#fig6){ref-type="fig"}I and 6J), raising the possibility that they correspond to abnormal extensions of centriolar microtubules.

To test this hypothesis, we carried out correlative light and electron microscopy (CLEM; [Figures 7](#fig7){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}). In line with previous observations ([@bib30], [@bib42], [@bib45]), we found that cells overexpressing YFP-CPAP and depleted of endogenous CPAP harbored overly long centrioles, in which microtubules extended from the distal end of the centriole ([Figures 7](#fig7){ref-type="fig"}B and 7F; compare with 7A and 7E). Strikingly, cells expressing YFP-CPAP-ΔLID also exhibited microtubule extensions from the distal end of the centriole, which attained several microns in some cases ([Figures 7](#fig7){ref-type="fig"}C and 7G). To ensure that such figures represented centriole fibers (i.e., devoid of Centrin) and not overly long centrioles (i.e., bearing Centrin), we carried out further CLEM experiments using tagRFP-Centrin 1 as an additional marker. In agreement with our immunofluorescence analysis, we found that YFP-CPAP-ΔLID centriole fibers were indeed microtubules extending from the distal end of centrioles ([Figures 7](#fig7){ref-type="fig"}D and 7H). We conclude that the activities of LID and SAC can prevent aberrant overextension of centriolar microtubules.

Discussion {#sec3}
==========

Our study provides fundamental insights into the mechanisms by which the evolutionarily conserved family of CPAP/SAS-4 proteins regulate the growth of centriolar microtubules, thus contributing to setting organelle size. Whereas the crystal structure of the G box of CPAP, either alone or in complex with a peptide derived from the centriolar protein STIL, has been solved ([@bib52], [@bib13], [@bib20]), high-resolution structural information on the evolutionarily conserved domains interacting with tubulin and microtubules was lacking, precluding full understanding of how CPAP regulates centriole biogenesis. The structural and biophysical data presented here reveal a dual binding mode between tubulin and the LID plus SAC domains of PN2-3, explaining its tubulin-sequestering and microtubule-destabilizing activities ([@bib22], [@bib12], [@bib23]). The finding that LID binds at the tip of β-tubulin, in combination with the structural model suggesting that PN2-3 can bind the terminal β-tubulin subunits on the outside of a microtubule, strongly suggested that PN2-3 represents an autonomous microtubule plus-end targeting domain in CPAP.

To test whether this is the case, we performed dynamic microtubule reconstitution experiments and indeed found that the sequential arrangement of LID, SAC, and MBD in a dimeric configuration localizes CPAP~mini~ to growing microtubule plus ends. The plus-end localization of CPAP~mini~ is unlikely to depend on co-polymerization with tubulin, because tip localization is observed at CPAP~mini~ concentrations that are several orders of magnitude lower than that of tubulin. Analysis of the behavior of single CPAP~mini~ molecules in our in vitro reconstitution system showed that the majority of CPAP~mini~ molecules bound to microtubule plus ends directly. CPAP~mini~ also displayed one-dimensional diffusion along the microtubule lattice, as described previously for other microtubule-end-interacting proteins ([@bib10], [@bib5], [@bib21], [@bib35]); however, diffusion did not seem to be a major contributing factor responsible for the recruitment of CPAP~mini~ to microtubule plus ends. Notably, in the context of a centriole, CPAP is expected to be organized in a precise manner along the inside of the centriole wall where it binds STIL, and is thus very likely not diffusive ([@bib20]).

Our reconstitution data revealed that depending on the conditions, microtubule-tip-localized CPAP~mini~ slows down microtubule growth 5- to 8-fold and that only a few CPAP~mini~ molecules suffice to induce this effect. Based on the structural and biophysical results, we propose that the LID and SAC domains of CPAP~mini~ bind terminal β-tubulin subunits exposed at the microtubule plus ends and thereby occlude the binding sites for the incoming tubulin dimers. The ability of PN2-3 to block longitudinal tubulin-tubulin interactions is reminiscent of the tubulin-sequestering protein stathmin and the microtubule plus-end capping ligands DARPin D1, eribulin, and maytansine ([@bib14], [@bib38], [@bib43], [@bib39]). However, in striking contrast to these microtubule-destabilizing and polymerization-blocking agents, CPAP~mini~ stabilizes microtubules by potently suppressing catastrophes and promoting rescues. The latter property can be attributed to the MBD, which binds strongly to the microtubule lattice and can autonomously induce rescues. The MBD is positively charged, and its binding to negatively charged microtubules likely involves an electrostatic mechanism, similar to that of microtubule lattice-binding regions of cytoplasmic microtubule regulators such as XMAP215/ch-TOG ([@bib10], [@bib49]). We assume that the MBD of CPAP~mini~ binds along, as well as between, protofilaments to stabilize microtubules.

Based on these considerations, we conclude that this particular mode of binding to microtubule plus ends, due to the combination of LID, SAC, and MBD, can "cap" and stabilize terminal tubulin dimers ([Figure 4](#fig4){ref-type="fig"}H). We postulate that in this state, a capped protofilament can only be elongated by an incoming tubulin dimer if the LID domain is released and frees the interaction site needed for establishing longitudinal tubulin-tubulin contacts. The release of LID in turn weakens the CPAP~mini~ microtubule plus-end interaction and either promotes CPAP~mini~ detachment or enables the liberated PN2-3 domain to cap the newly elongated protofilament or a neighboring one. Notably, slowing microtubule growth normally promotes catastrophes by reducing the size of the GTP cap ([@bib48], [@bib25]). Accordingly, microtubule polymerization suppressors typically act as microtubule depolymerases. However, exceptions to this rule are known, including the kinesin-4 family members Xklp1/KIF4 and KIF21A which, similarly to CPAP~mini~, can suppress both microtubule growth and catastrophes ([@bib9], [@bib6], [@bib47]). The molecular basis of kinesin-4-mediated microtubule growth inhibition is not understood, but is very likely distinct from that of CPAP~mini~, because both Xklp1/KIF4 and KIF21A are molecular motors that can move along microtubules and accumulate at microtubule plus ends due to their processive motility ([@bib6], [@bib47]). In contrast, CPAP presents a unique arrangement of tubulin-binding and microtubule-lattice-binding domains, which together have the potential to recognize, cap, and stabilize microtubule plus ends, a mechanism that to our knowledge has not been previously described for any microtubule regulator.

In cells, centriolar microtubules grow very slowly and processively as judged from the analysis of specimens prepared from different stages of the cell cycle ([@bib31], [@bib11]). However, the mechanisms underlying such slow and regulated elongation have remained elusive. Our study reveals that CPAP plays a critical dual role in ensuring that this is the case. First, our data indicate that a pivotal function of CPAP is to stabilize centriolar microtubules via its MBD, which likely explains why this domain is essential for centriole assembly. Second, although the capacity of LID to cap microtubule plus ends is not essential for this stabilization function, and thus for centriole formation, it exerts a negative role by limiting microtubule extension from the distal end of centrioles. The SAC domain, which interacts with the lateral side of tubulin dimers, can contribute to both microtubule stabilization and capping functions, potentially explaining why mutations in SAC affect centriole formation more strongly than those in LID. These considerations can at least partially explain why centrioles overelongate when CPAP dosage is increased ([@bib30], [@bib42], [@bib45]); however, additional mechanisms likely control the activity of CPAP domains in cells. Our in vitro data revealed that approximately two CPAP~mini~ dimers are sufficient to limit the growth rate of a single microtubule, suggesting that CPAP works at substoichiometric levels. In the context of the centriolar microtubule wall, we expect approximately two CPAP dimers to be able to access the microtubule tips of each triplet from the luminal side of the centriole ([Figure S6](#mmc1){ref-type="supplementary-material"}) ([@bib20], [@bib44], [@bib46]).

Overall, our results reveal that CPAP is a highly specialized microtubule plus-end regulator that acts as a molecular cap to ensure slow and processive growth of centriolar microtubules. Given that endogenous CPAP is present primarily in the proximal region of mature centrioles ([@bib30], [@bib42], [@bib45]), we propose that CPAP activity is most critical during the early stages of centriole elongation. Upon overexpression of the wild-type protein, excess CPAP molecules localize along the entire length of centrioles and could cause overelongation of centriolar microtubules due to the microtubule stabilization activity of ectopic CPAP. Furthermore, we speculate that upon overexpression of a mutant protein lacking LID-domain function, overelongation of centriolar microtubules is exacerbated due to the lack of capping function ([Figure S6](#mmc1){ref-type="supplementary-material"}).

We note that microtubule growth rates obtained in vitro upon CPAP~mini~ addition are still some three orders of magnitude faster than those estimated for centriolar microtubules in cells ([@bib31], [@bib11]). Regions of CPAP outside of the microtubule- and tubulin-binding domains, including the G box, that may organize CPAP molecules along the entire length of the microtubule wall in a precise manner ([@bib20]), as well as post-translational modifications, could be important to further bolster CPAP activity; these features are not recapitulated by the CPAP~mini~ and CPAP~long~ constructs used in our study. In addition, other centriolar proteins have been implicated in controlling centriole length, including the CPAP-interacting proteins CEP120, CEP135, and Centrobin ([@bib19], [@bib33], [@bib34]). It will be of prime interest to assess on a mechanistic level how these proteins cooperate to impact on CPAP function or otherwise contribute to regulate organelle size.

Experimental Procedures {#sec4}
=======================

Protein/Peptide Preparation and Isothermal Titration Calorimetry {#sec4.1}
----------------------------------------------------------------

Standard protein production in bacteria and peptide synthesis is described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. ITC experiments were performed at 25°C using an ITC200 system (Microcal). Proteins were buffer-exchanged to BRB80 (80 mM PIPES-KOH \[pH 6.8\] supplemented with 1 mM MgCl~2~ and 1 mM EGTA) supplemented with 0.5 mM tris(2-carboxyethyl)phosphine. 0.1--0.4 mM PN2-3 variants in the syringe were injected stepwise into 10--20 μM tubulin solutions in the cell. The resulting heats were integrated and fitted in Origin (OriginLab) using the standard "one set of sites" model provided by the software package.

Structure Determination {#sec4.2}
-----------------------

Structure solution by X-ray crystallography is described in full in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. In brief, equimolar amounts of D1, PN2-3, and subtilisin-treated tubulin were mixed and the PN2-3-tubulin-D1 complex was concentrated to ∼20 mg/ml. PN2-3-tubulin-D1 samples were complemented with 0.2 mM GDP, 1 mM colchicine, and 5 mM DTT before setting up sitting-drop vapor diffusion crystallization trials. Crystals were obtained in a condition containing 20% polyethylene glycol (PEG) 550 monomethyl ether and 0.1 M 2-(N-morpholino)ethanesulfonic acid (pH 6.5). X-Ray diffraction data were collected at 100 K at beamline X06DA at the Swiss Light Source. The PN2-3-tubulin-D1 structure was solved by molecular replacement using the αβ-tubulin-D1 complex structure as a search model (PDB: [4DRX](pdb:4DRX){#intref0015}). Data collection and refinement statistics are given in [Table S2](#mmc1){ref-type="supplementary-material"}.

In Vitro Reconstitution Assays {#sec4.3}
------------------------------

Protein purification for in vitro reconstitution assays is described in full in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Reconstitution of microtubule growth dynamics in vitro was performed as described previously ([@bib35]). In brief, flow chambers were functionalized by sequential incubation with 0.2 mg/ml PLL-PEG-biotin (Susos) and 1 mg/ml NeutrAvidin (Invitrogen) in MRB80 buffer (80 mM piperazine-N,N′-bis(2-ethanesulfonic acid) \[pH 6.8\] supplemented with 4 mM MgCl~2~ and 1 mM EGTA). GMPCPP-microtubule seeds were attached to coverslips through biotin-NeutrAvidin interactions. The reaction mix with or without CPAP~mini~ proteins (MRB80 buffer supplemented with 15 μM tubulin, 0.5 μM rhodamine-tubulin, 50 mM KCl, 1 mM guanosine triphosphate, 0.2 mg/ml κ-casein, 0.1% methylcellulose, and oxygen scavenger mix \[50 mM glucose, 400 μg/ml glucose oxidase, 200 μg/ml catalase, and 4 mM DTT\]) was added to the flow chamber. Flow chambers were sealed and dynamic microtubules were imaged immediately at 30°C using TIRF microscopy. Intensity analysis for CPAP~mini~ along microtubules, single-molecule fluorescence intensity analysis of CPAP~mini~, CPAP~mini~ molecule counting at microtubule tips, analysis of microtubule plus-end dynamics, and statistical analysis procedures are all described in full in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunofluorescence, Antibodies, and Microscopy {#sec4.4}
----------------------------------------------

Cells were grown on glass coverslips and fixed in methanol for 7 min at −20°C. Cold treatment was carried out by incubating cells in ice-cold PBS, on ice, for 1 hr before fixation. Cells were permeabilized using 0.2% Triton X-100, washed in PBS and 0.01% Triton X-100, and blocked for 1 hr in PBS, 1% BSA, and 2% fetal calf serum. All antibodies were diluted in the blocking solution and incubated for either 1 hr at room temperature or ∼12 hr at 4°C. Primary antibodies were mouse anti-α-tubulin (DM1a, Sigma), mouse "20H5" anti-centrin-2 (a gift from J. Salisbury), rabbit anti-hPOC5 ([@bib3]; a gift from M. Bornens), rabbit anti-CEP63 (Millipore 06-1292), goat anti-GFP (Abcam ab6673), and rabbit anti-GFP (a gift from V. Simanis). Secondary antibodies were goat anti-rabbit Alexa Fluor 488, goat anti-mouse Alexa Fluor 568, donkey anti-goat Alexa Fluor 488, donkey anti-mouse Alexa Fluor 568, and donkey anti-rabbit Alexa Fluor 647 (Invitrogen). All primary antibodies were diluted 1,000-fold, except Centrin 2 (2000×) and anti-α-tubulin (5000×). All secondary antibodies were diluted 1,000-fold. Samples were washed three times between, and after, antibody incubations and incubated with 1 μg/ml Hoechst in PBS prior to mounting in PBS, 90% glycerol, and 4% N-propyl gallate.

Confocal imaging was carried out using a Zeiss LSM 700 microscope with a Plan-Apochromat 63× oil-immersion objective, NA 1.40. Z sections were imaged at an interval of ∼0.2 μm. All images shown are maximum-intensity projections and were processed using Fiji ([@bib41]), maintaining relative intensities within a series.

Correlative Light and Electron Microscopy {#sec4.5}
-----------------------------------------

CLEM is described in full in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. In brief, endogenous CPAP was depleted by RNAi for 72 hr, simultaneous with induction of the transgene. For dual marker experiments, cells were transfected with a tagRFP-Centrin 1 expression vector 16 hr prior to fixation. Cells were fixed, then washed thoroughly with 0.1 M cacodylate buffer (pH 7.4), and imaged by light microscopy. Immediately afterward, samples were post-fixed for 40 min in 1.0% osmium tetroxide, then 30 min in 1.0% uranyl acetate in water, before being dehydrated through increasing concentrations of alcohol and then embedded in Durcupan ACM resin (Fluka). The coverslips were then placed face down on a glass slide coated with mold-releasing agent (Glorex), with approximately 1 mm of resin separating the two. These regions were mounted on blank resin blocks with acrylic glue and trimmed with glass knives to form a block ready for serial sectioning. Series of between 150 and 300 thin sections (50 nm thickness) were cut with a diamond knife mounted on an ultramicrotome (Leica UC7). These sections were contrasted with lead citrate and uranyl acetate and images taken using an FEI Spirit transmission electron microscope equipped with an Eagle CCD camera.
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Supplemental Information includes Supplemental Experimental Procedures, six figures, and three tables and can be found with this article online at [http://dx.doi.org/10.1016/j.devcel.2016.04.024](10.1016/j.devcel.2016.04.024){#intref0025}.

![Structure of the Tubulin-PN2-3 Complex\
(A) Domain organization of human CPAP, with indication of amino acid numbers at domain boundaries. The PN2-3 region is shown magnified below, with residue conservation among CPAP/SAS-4 proteins in *Homo sapiens*, *Mus musculus*, *Gallus gallus*, *Danio rerio*, *Xenopus tropicalis*, *Drosophila melanogaster*, and *Caenorhabditis elegans*. Black and gray shadings indicate different degrees of residue conservation. Blue and olive bars highlight the LID and SAC domains, respectively. Asterisks indicate residues that have been mutated in this study. MBD, microtubule-binding domain; CC, coiled coil.\
(B) Overall view of the complex formed between PN2-3 (SAC residues in olive), αβ-tubulin (gray), and D1 (cyan). The N and C termini of SAC are indicated. The dashed box depicts the area shown in (C).\
(C) Close-up view of the interaction between SAC (olive sticks) and tubulin (gray). Selected secondary structural elements of tubulin are labeled in bold purple letters. Residues at the tubulin-SAC interface are labeled in black and olive (SAC).\
(D) Location of the D1 (cyan), eribulin (brown), and maytansine sites (pink) on β-tubulin. Note that eribulin binds to the vinca site on β-tubulin. The N terminus of SAC (olive) is shown. The blue oval represents the expected binding region of LID.\
See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Interactions of PN2-3 with Tubulin and Microtubules\
(A--C) ITC analysis of interactions between indicated PN2-3 variants and tubulin. D1, DARPin; Er, eribulin; Ma, maytansine. Note that eribulin and maytansine bind to the vinca site and maytansine site on β-tubulin, respectively ([@bib15], [@bib39], [@bib43]).\
(D) Binding of SAC (olive surface representation) and LID (schematically represented by a blue oval) in the context of a microtubule plus end, with three protofilaments (PF1--PF3) being represented. Light-gray surface representation, β-tubulin; dark-gray surface representation, α-tubulin. The plus (+) and minus (−) ends of the microtubule are indicated on the right.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Effects of CPAP~mini~ on Dynamic Microtubules\
(A) Schematic of CPAP~mini~ construct.\
(B) Single frame of a time-lapse movie of rhodamine (Rh)-labeled microtubules growing from rhodamine-GMPCPP seeds in the presence of CPAP~mini~. Arrows point to CPAP~mini~ microtubule tip accumulation.\
(C) Normalized mean intensity profiles for CPAP~mini~ and rhodamine-tubulin obtained from 30 microtubules. Error bars represent SEM.\
(D) Kymographs of microtubule growth at the plus (+) and minus (−) end from a rhodamine-GMPCPP seed with 50 nM mCherry-CAMSAP3 and 100 nM CPAP~mini~.\
(E) Kymographs of microtubule plus-end dynamics with rhodamine-tubulin alone or together with 100 nM CPAP~mini~.\
(F) Kymographs of microtubule plus-end dynamics with 20 nM mCherry-EB3 alone or together with 100 nM CPAP~mini~.\
(G) Kymographs of microtubule plus-end dynamics with rhodamine-tubulin and 100 nM of the two indicated CPAP~mini~ variants.\
(H--M) Microtubule plus-end growth rate, catastrophe frequency, and rescue frequency in the presence of rhodamine-tubulin alone or together with 20 nM mCherry-EB3 and 100 nM of the indicated CPAP~mini~ variants. ∼100--200 microtubule growth events from two to four independent experiments were analyzed per condition. Error bars represent SEM.\
Scale bars in (D--G) represent 2 μm (horizontal) and 60 s (vertical). See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Counting of CPAP~mini~ Molecules at Microtubule Plus Ends\
(A) Kymographs illustrating growth dynamics of microtubule plus ends in the presence of 20 nM mCherry-EB3 and indicated concentrations of CPAP~mini~. Only the CPAP~mini~ channel is shown. Scale bars represent 2 μm (horizontal) and 60 s (vertical).\
(B) Microtubule growth rates at indicated concentrations of CPAP~mini~ in the presence of 20 nM mCherry-EB3. Error bars represent SEM.\
(C) Distribution of fluorescence intensities for single molecules of GFP (blue, mean intensity value 3.4 × 10^3^ ± 1.6 × 10^3^) and CPAP~mini~ (green, mean intensity value 6.2 × 10^3^ ± 3.1 × 10^3^). Mean intensity values are reported as means ± SD.\
(D) Distribution of fluorescence intensity values for single immobilized CPAP~mini~ molecules (green, mean intensity value = 8.3 × 10^3^ ± 3.2 × 10^3^) compared to CPAP~mini~ (100 nM) molecules at microtubule tips (red, mean intensity value 15.2 × 10^3^ ± 4.7 × 10^3^). Mean intensity values are reported as means ± SD.\
(E) Distributions of the numbers of CPAP~mini~ molecules on microtubule plus ends at indicated protein concentrations of CPAP~mini~. At 100 nM, a concentration sufficient to strongly suppress microtubule growth, ∼2 CPAP~mini~ dimers were bound to microtubule tips (green curve).\
(F) Kymographs of dynamic microtubules grown in the presence of 100 nM CPAP~mini~-mCherry, 5 nM CPAP~mini~-GFP, and rhodamine-tubulin, demonstrating CPAP~mini~ single-molecule behavior at the tip and lattice. Plus ends are indicated by black arrows. White arrows point to examples showing both lattice diffusion and tip tracking, while molecules displaying stationary behavior at the microtubule tips are indicated by arrowheads. Scale bars represent 2 μm (horizontal) and 2 s (vertical).\
(G) Mean dwell times for CPAP~mini~ on the microtubule lattice (mean time = 0.51 ± 0.01, n = 258) and tip (mean time = 1.67 ± 0.06, n = 755) obtained from the dwell-time distributions; reported means were corrected for photobleaching. Error bars represent the error of fit (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).\
(H) Working model of how CPAP~mini~ ensures slow processive microtubule growth. CPAP recognizes the microtubule plus end via tandemly arranged LID, SAC, and MBD domains (I). This stabilizes the interaction of the terminal tubulin dimers, "caps" the corresponding protofilaments, and stabilizes the microtubule lattice. "Opening" of LID (dashed curved arrow), spontaneously and/or induced by an incoming tubulin dimer (II), enables processive microtubule tip elongation (III).\
See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Effect of PN2-3 Mutations on CPAP Cellular Function\
(A--H) Mitotic U2OS FlpIn TREX cell lines without transgene (A and B) or expressing the indicated YFP-CPAP variants (C--H), treated with control siRNA (A) or siRNA targeting endogenous CPAP (B--H), stained with antibodies against Centrin 2 (magenta) and GFP (green); DNA in blue. Scale bars in (A) apply to all images and represent 10 μm in main image and 1 μm in insets.\
(I) Percentage of cells showing successful centriole duplication (≥4 Centrin 2 foci). Bars show the mean of three experimental repeats; circles indicate the individual values for each experiment. n \> 100 cells analyzed for each condition and per experiment. Two-tailed unequal variance t-tests were used to compare each CPAP mutant to the wild type transgene, with the p values \< 0.05 for all samples except FEY/AAA (p = 0.0784). Full dataset is shown in [Figure S4](#mmc1){ref-type="supplementary-material"}A.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Fibers Extend from Centrioles upon Expression of CPAP Lacking the LID Domain\
(A--D) U2OS cells expressing indicated YFP-CPAP variants and depleted of endogenous CPAP by RNAi, stained with antibodies against Centrin 2 (magenta) and GFP (green). (A) Quantification of the YFP structures illustrated in (B--D) (n \> 100 per sample). Note that the total exceeds 100% here and in (E--G) because some cells contain multiple types of structure. Scale bar, 1 μm.\
(E--G) Proportion of YFP-CPAP-ΔLID expressing cells with centriole fibers (E and F) or PCM fibers (G). Percentages are the mean of three experiments ± SD; n = 9, 17, and 26 cells, respectively. Scale bar, 1 μm.\
(H) Length of overly long centrioles and of centriole fibers in the indicated conditions determined using GFP immunofluorescence. n = 42, 22, and 37 cells, respectively. Bars indicate the mean, squares indicate the minimum and maximum values, and error bars indicate the SD. Student\'s two-sample two-tailed unequal variance t test comparing ΔLID overly long centrioles and centriole fibers with CPAP-induced overly long centrioles: ^∗∗∗^p \< 0.001; n.s., not significant.\
(I and J) YFP-CPAP-ΔLID cells without (I) or with (J) 1 hr incubation on ice stained with antibodies against α-tubulin (gray), GFP (green), and the distal centriole protein POC5 (magenta). Arrowheads indicate end of centrioles from which emanate fibers, as determined by the POC5 signal. Note that the signal of YFP-CPAP-ΔLID along the centriole fiber becomes sparser following ice-induced microtubule depolymerization. Scale bars represent 10 μm (main image) and 5 μm (inset).](gr6){#fig6}

![Centriole Fibers Are Centriolar Microtubule Extensions\
(A--H) CLEM of cells expressing tagRFP-Centrin 1 (Cell 1; A, E), YFP-CPAP and tagRFP-Centrin 1 (Cell 2; B, F), YFP-ΔLID (Cell 3; C, G), or YFP-ΔLID plus tagRFP-Centrin-1 (Cell 4; D, H), and simultaneously depleted of endogenous CPAP using RNAi (Cells 2--4). (A--D) Fluorescence microscopy images of the region of interest in each cell. Scale bar, 1 μm. (E--H) Corresponding high-magnification electron micrographs of the boxed region in (A--D), showing one 50 nm section from a serial section series. Yellow arrowheads indicate microtubule extensions from the distal ends of centrioles. Scale bars, 500 nm. Ten cells expressing YFP-ΔLID were analyzed, which contained a total of 28 centrioles. Of these, three were centrioles with an apparent normal length and structure, two were overly long centrioles without further microtubule extensions, four exhibited PCM fibers, whereas 19 harbored microtubule extensions from their distal ends (as illustrated in G and H). Of these 19 centrioles, six came from the experiment where cells were also expressing tagRFP-Centrin 1 and could therefore be unambiguously classified as centriole fibers (i.e., without tagRFP-Centrin 1 signal) rather than overly long centrioles.\
See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
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